cholesterol-lowering drugs
NewAmsterdam’s CETP Inhibitor Obicetrapib Achieves Phase 3 Success but Fails to Meet Investor Expectations
NewAmsterdam Pharma, CETP inhibitors, obicetrapib, cholesterol-lowering drugs, Phase 3 trials, investor expectations, LDL cholesterol reduction